Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib Plus Dostarlimab for Small Cell Lung Cancer and High-Grade Neuroendocrine Carcinomas
NCT04701307Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2021; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04701307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701307.